A Phase 4 interventional study of placebo and pregabalin (Lyrica) in Fibromyalgia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 36 sites in 4 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-01-28.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing pregabalin in Fibromyalgia — 6 open to participants now, 6 under way, none of them phase 3. Pregabalin · Fibromyalgia.
Among the 30 studies testing pregabalin in Fibromyalgia, this one is the 21st largest by enrollment, is one of 3 that started in 2010, is one of 7 in phase 4, and was the 12th registered.
1,244 studies on the registry are indexed under Fibromyalgia; 255 are open to participants now.
Browse Fibromyalgia studies →6 of the 30 studies testing pregabalin in Fibromyalgia are open now, in 2 countries. Recruiting first, the newest first:
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18–65
By country, each count listing its studies:
Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 160 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 12 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 14 · Phase 4 7
First in 2004; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 107 is above the median of 60 across 938 interventional studies indexed under Fibromyalgia.
Median enrollment 199 across the 30 interventional studies. Of the 22 that completed or were terminated, 10 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 30 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
19 studies in Fibromyalgia by Viatris Inc.: none open now, none under way, none of them phase 3. Of 19 finished, 13 (68%) have results posted.
Among the 19 studies in Fibromyalgia by Viatris Inc., this one is the 13th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2010, is one of 2 in phase 4, and was the 12th registered.
Viatris Inc.’s Fibromyalgia studies by the year they started, since 2004.
4 of the studies testing pregabalin in Fibromyalgia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07186751Beijing Tiantan HospitalThe Efficacy and Safety of Pregabalin Combined With Venlafaxine in Patients With Fibromyalgia | 2027-06-30 |
| NCT07230197Beijing Tiantan HospitalThe Efficacy and Safety of Pregabalin Combined With Dexmedetomidine in Patients With Fibromyalgia | 2027-06-30 |
| NCT07208357Beijing Tiantan HospitalThe Efficacy and Safety of Pregabalin Combined With Toludesvenlafaxine in Patients With Fibromyalgia | 2027-06-30 |
| NCT07171320Beijing Tiantan HospitalThe Efficacy and Safety of Pregabalin Combined With Desvenlafaxine in Patients With Fibromyalgia | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 30 studies testing pregabalin in Fibromyalgia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 19 in Fibromyalgia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will compare pregabalin with placebo over a 15 week period in adolescents with fibromyalgia aged 12-17 years to evaluate the safety and efficacy of pregabalin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: placebo
Drug: pregabalin (Lyrica)
matching placebo capsules twice daily.
75-450mg/day pregabalin dose optimised at start of study
Change From Baseline to Week 15 in Mean Pain Diary Score
The Primary Endpoint is based on the daily pain diary, and is defined as change from baseline to Week 15 in mean pain diary score. The daily pain diary consists of an 11-point numeric rating scale ranging from zero (no pain) to 10 (worst possible pain). The patients rate their pain during the past 24 hours by choosing the appropriate number between 0 ("no pain") and 10 ("worst possible pain").
Time frame: Week 15
Change From Baseline to Week 15 in Mean Sleep Quality Diary Score
Change from Baseline to endpoint in mean sleep quality score from the daily sleep diary, defined as the mean of the last 7 diary entries prior to Visit 10 in the study while the participant is on study medication. The daily quality of sleep diary consists of an 11-point numeric rating scale with which the patient rates the quality of their sleep during the past 24 hours. Zero indicates "best possible sleep" and 10 indicates "worst possible sleep".
Time frame: Week 15
Mean Change From Baseline to Weekly Mean Pain Score - Daily Pain Numeric Rating Scale (NRS)
Mean pain score was calculated for each week during the double-blind treatment phase (Week 1 to Week 15). For each week, only days up to the last day on study medication were considered. A minimum of 4 pain diaries were required to calculate the mean pain score. The pain NRS consists of an 11 point NRS ranging from 0 (no pain) to 10 (worst possible pain).
Time frame: Baseline to Week 15
Mean Change From Baseline to Weekly Mean Sleep Quality Score (NRS)
Mean sleep quality score was calculated for each week during the double-blind treatment phase (Week 1 to Week 15). A minimum of 4 sleep diaries are required to calculate the mean pain score. The daily quality of sleep diary consists of an 11-point numeric rating scale with which the patient rates the quality of their sleep during the past 24 hours. Zero indicates "best possible sleep" and 10 indicates "worst possible sleep".
Time frame: Baseline to Week 15
Change From Baseline to Week 15 in Mean Pain Numeric Rating Scale (1 Week Recall Period)
The weekly pain numeric rating scale (Weekly Pain NRS) consists of an 11-point NRS ranging from 0 (no pain) to 10 (worst possible pain), where higher scores indicate greater degree of impairment. Participants choose the number that best describes the pain during the last week.
Time frame: Week 15
Proportion of 30% Responders in Weekly Mean Pain Score (NRS) at Week 15
At each visit, participants with at least 30% reduction from Baseline in mean pain score were defined as a 30% responder at the visit. The pain NRS consists of an 11 point NRS ranging from 0 (no pain) to 10 (worst possible pain).
Time frame: Week 15
Proportion of 50% Responder in Weekly Mean Pain Score (NRS) at Week 15
At each visit, participants with at least 50% reduction from Baseline in mean pain score were defined as a 50% responder at the visit. The pain NRS consists of an 11 point NRS ranging from 0 (no pain) to 10 (worst possible pain).
Time frame: Week 15
Proportion of Patient Global Impression Change (PGIC) at Week 15
Responder rates based on PGIC was derived and tabulated by treatment group. A responder was defined as a participant who reports much improved or very much improved. The PGIC is a patient-rated single item that measures patient's perception of change in their overall status since starting study medication on a scale ranging from 1 (very much improved) to 7 (very much worse).
Time frame: Week 15
A total of 147 participants were screened, 107 participants were randomized to treatment. The 107 randomized participants were recruited in 4 countries at 23 study centers.
| Milestone | Pregabalin | Placebo |
|---|---|---|
| Started | 54 | 53 |
| Completed | 44 | 36 |
| Not completed | 10 | 17 |
| Withdrew: Adverse event | 4 | 4 |
| Withdrew: Protocol violation | 0 | 2 |
| Withdrew: Withdrawal by subject | 5 | 7 |
| Withdrew: Other reasons | 1 | 1 |
| Withdrew: Insufficient clinical response | 0 | 3 |
The Primary Endpoint is based on the daily pain diary, and is defined as change from baseline to Week 15 in mean pain diary score. The daily pain diary consists of an 11-point numeric rating scale ranging from zero (no pain) to 10 (worst possible pain). The patients rate their pain during the past 24 hours by choosing the appropriate number between 0 ("no pain") and 10 ("worst possible pain").
| Units on a scale | Pregabalin | Placebo |
|---|---|---|
| Change From Baseline to Week 15 in Mean Pain Diary Score | -1.60 ± 0.32 | -0.94 ± 0.31 |
Change from Baseline to endpoint in mean sleep quality score from the daily sleep diary, defined as the mean of the last 7 diary entries prior to Visit 10 in the study while the participant is on study medication. The daily quality of sleep diary consists of an 11-point numeric rating scale with which the patient rates the quality of their sleep during the past 24 hours. Zero indicates "best possible sleep" and 10 indicates "worst possible sleep".
| Units on a scale | Pregabalin | Placebo |
|---|---|---|
| Change From Baseline to Week 15 in Mean Sleep Quality Diary Score | -1.13 ± 0.30 | -0.94 ± 0.31 |
Mean pain score was calculated for each week during the double-blind treatment phase (Week 1 to Week 15). For each week, only days up to the last day on study medication were considered. A minimum of 4 pain diaries were required to calculate the mean pain score. The pain NRS consists of an 11 point NRS ranging from 0 (no pain) to 10 (worst possible pain).
| Units on a scale | Pregabalin | Placebo |
|---|---|---|
| Week 1 (N= 52, 49) | -0.48 ± 0.25 | -0.41 ± 0.26 |
| Week 2 (N= 54, 47) | -1.11 ± 0.25 | -0.48 ± 0.26 |
| Week 3 (N= 52, 44) | -1.27 ± 0.25 | -0.45 ± 0.26 |
| Week 4 (N= 50, 46) | -1.45 ± 0.25 | -0.55 ± 0.26 |
| Week 5 (N= 49, 44) | -1.27 ± 0.25 | -0.59 ± 0.26 |
| Week 6 (N= 49, 44) | -1.47 ± 0.25 | -0.51 ± 0.27 |
| Week 7 (N= 48, 42) | -1.67 ± 0.25 | -0.77 ± 0.27 |
| Week 8 (N= 46, 44) | -1.65 ± 0.25 | -0.59 ± 0.27 |
| Week 9 (N= 46, 42) | -1.61 ± 0.26 | -0.66 ± 0.27 |
| Week 10 (N= 45, 40) | -1.82 ± 0.26 | -0.85 ± 0.27 |
| Week 11 (N= 44, 38) | -1.93 ± 0.26 | -1.07 ± 0.28 |
| Week 12 (N= 43, 34) | -1.75 ± 0.26 | -0.78 ± 0.28 |
| Week 13 (N= 42, 33) | -1.75 ± 0.27 | -1.01 ± 0.29 |
| Week 14 (N= 41, 34) | -2.01 ± 0.27 | -1.11 ± 0.29 |
| Week 15 (N= 35, 33) | -1.90 ± 0.28 | -1.16 ± 0.30 |
Mean sleep quality score was calculated for each week during the double-blind treatment phase (Week 1 to Week 15). A minimum of 4 sleep diaries are required to calculate the mean pain score. The daily quality of sleep diary consists of an 11-point numeric rating scale with which the patient rates the quality of their sleep during the past 24 hours. Zero indicates "best possible sleep" and 10 indicates "worst possible sleep".
| Units on a scale | Pregabalin | Placebo |
|---|---|---|
| Week 1 (N= 52, 49) | -0.52 ± 0.25 | -0.30 ± 0.26 |
| Week 2 (N= 54, 47) | -0.84 ± 0.25 | -0.65 ± 0.26 |
| Week 3 (N= 52, 44) | -0.89 ± 0.25 | -0.44 ± 0.26 |
| Week 4 (N= 50, 46) | -1.03 ± 0.25 | -0.54 ± 0.26 |
| Week 5 (N= 49, 44) | -0.99 ± 0.25 | -0.61 ± 0.27 |
| Week 6 (N= 49, 44) | -1.18 ± 0.25 | -0.54 ± 0.27 |
| Week 7 (N= 48, 42) | -1.30 ± 0.25 | -0.81 ± 0.27 |
| Week 8 (N= 46, 44) | -1.43 ± 0.25 | -0.42 ± 0.27 |
| Week 9 (N= 46, 42) | -1.38 ± 0.26 | -0.81 ± 0.27 |
| Week 10 (N= 45, 40) | -1.43 ± 0.26 | -0.66 ± 0.27 |
| Week 11 (N= 44, 38) | -1.39 ± 0.26 | -0.95 ± 0.28 |
| Week 12 (N= 43, 34) | -1.38 ± 0.26 | -0.77 ± 0.28 |
| Week 13 (N= 42, 33) | -1.34 ± 0.27 | -1.00 ± 0.29 |
| Week 14 (N= 41, 34) | -1.36 ± 0.27 | -0.94 ± 0.29 |
| Week 15 (N= 35, 33) | -1.25 ± 0.28 | -1.08 ± 0.30 |
The weekly pain numeric rating scale (Weekly Pain NRS) consists of an 11-point NRS ranging from 0 (no pain) to 10 (worst possible pain), where higher scores indicate greater degree of impairment. Participants choose the number that best describes the pain during the last week.
| Units on a scale | Pregabalin | Placebo |
|---|---|---|
| Change From Baseline to Week 15 in Mean Pain Numeric Rating Scale (1 Week Recall Period) | -1.64 ± 0.31 | -0.77 ± 0.30 |
At each visit, participants with at least 30% reduction from Baseline in mean pain score were defined as a 30% responder at the visit. The pain NRS consists of an 11 point NRS ranging from 0 (no pain) to 10 (worst possible pain).
| percentage of participants | Pregabalin | Placebo |
|---|---|---|
| Proportion of 30% Responders in Weekly Mean Pain Score (NRS) at Week 15 | 42.6 | 38.8 |
At each visit, participants with at least 50% reduction from Baseline in mean pain score were defined as a 50% responder at the visit. The pain NRS consists of an 11 point NRS ranging from 0 (no pain) to 10 (worst possible pain).
| percentage of participants | Pregabalin | Placebo |
|---|---|---|
| Proportion of 50% Responder in Weekly Mean Pain Score (NRS) at Week 15 | 20.4 | 10.2 |
Responder rates based on PGIC was derived and tabulated by treatment group. A responder was defined as a participant who reports much improved or very much improved. The PGIC is a patient-rated single item that measures patient's perception of change in their overall status since starting study medication on a scale ranging from 1 (very much improved) to 7 (very much worse).
| percentage of participants | Pregabalin | Placebo |
|---|---|---|
| Very much improved | 16.3 | 2.3 |
| Much improved | 36.7 | 27.3 |
| Minimally improved | 22.4 | 27.3 |
| No change | 18.4 | 38.6 |
| Minimally worse | 6.1 | 2.3 |
| Much worse | 0 | 2.3 |
| Very much worse | 0 | 0 |
Collected over Adverse events were reported from signing the informed consent until a follow-up visit (Week 16).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pregabalin | — | 1/54 (1.9%) | 33/54 (61.1%) |
| Placebo | — | 0/53 (0%) | 27/53 (50.9%) |
| Event | Pregabalin | Placebo |
|---|---|---|
| CholelithiasisHepatobiliary disorders | 1/54 | 0/53 |
| Major depressionPsychiatric disorders | 1/54 | 0/53 |
| Event | Pregabalin | Placebo |
|---|---|---|
| DizzinessNervous system disorders | 16/54 | 7/53 |
| NauseaGastrointestinal disorders | 12/54 | 5/53 |
| HeadacheNervous system disorders | 10/54 | 10/53 |
| Weight increasedInvestigations | 9/54 | 0/53 |
| FatigueGeneral disorders | 8/54 | 4/53 |
| Back painMusculoskeletal and connective tissue disorders | 3/54 | 5/53 |
| SomnolenceNervous system disorders | 5/54 | 2/53 |
| VomitingGastrointestinal disorders | 3/54 | 4/53 |
| Pharyngitis streptococcalInfections and infestations | 0/54 | 4/53 |
| Upper respiratory tract infectionInfections and infestations | 3/54 | 4/53 |
| Age, Continuous(years) | Pregabalin | Placebo | Total |
|---|---|---|---|
| Mean | 14.6 ± 1.2 | 14.7 ± 1.2 | 14.7 ± 1.2 |
| Sex: Female, Male(Participants) | Pregabalin | Placebo | Total |
|---|---|---|---|
| Female | 48 | 44 | 92 |
| Male | 6 | 9 | 15 |
The record gives a start of May 2010, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2015, 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →